In a significant victory for a Fortune 50 pharmaceutical company, the 3rd U.S. Circuit Court of Appeals vacated the trial court's class certification order following a nationwide class action alleging the company fixed the price of blood reagents. Our firm represented the pharmaceutical company in the litigation.